Respiratory tract neoplasm

Related records

Broader conditions (8)

• Cancer or benign tumor
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Human disease
• Neoplasm
• Neoplastic disease or syndrome
• Respiratory system disorder

Narrower conditions (180)

• Acinar lung adenocarcinoma
• Adenosquamous lung carcinoma
• Adult pulmonary Langerhans cell histiocytosis
• Alveoli adenoma
• Aryepiglottic fold cancer
• Asbestos-related lung carcinoma
• Basaloid large cell lung carcinoma
• Benign laryngeal neoplasm
• Benign neoplasm of epiglottis
• Benign neoplasm of glottis
• Benign neoplasm of nasal cavity
• Benign neoplasm of nasopharynx
• Benign neoplasm of pleura
• Benign neoplasm of subglottis
• Benign neoplasm of trachea
• Bronchial endocrine tumor
• Bronchial neoplasm
• Bronchogenic carcinoma
• Bronchus adenoma
• Bronchus cancer

Trials (60)

• (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
• (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
• (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
• 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
• A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
• A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
• A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
• A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
• A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
• A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
• A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
• A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
• A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
• Alberta Lung Cancer Screening Program
• Assessment of Probe Based Confocal Laser Endo-microscopy for In-vivo Diagnosis of Peripheral Lung Nodules and Masses.
• Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

Drugs in development (1)

• Alectinib Phase 2